GENB

Generate Biomedicines

• Simply Wall St·1d ago

  Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

• Simply Wall St·3d ago

  A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

• Benzinga·05/15 20:24

  NVIDIA Corporation Increases Stake In CoreWeave To 47,213,353 Shares, Maintains Holdings In Intel Corporation (214,776,632 Shares), Nebius Group N.V. (1,190,476 Shares), Nokia Corporation (166,389,351 Shares), Synopsys (4,821,717 Shares), Takes New Stakes In Coherent Corp. (7,788,161 Shares) Generate Biomedicines (833,325 Shares).

• Benzinga·05/15 20:19

  Nvidia Takes New Stake In Generate Biomedicines With 833,325 Shares

• Dow Jones·05/14 17:25

  Generate Biomedicines Price Target Raised to $22.00/Share From $20.00 by Morgan Stanley

• Dow Jones·05/14 17:25

  Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

• Benzinga·05/14 17:15

  Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

• TipRanks·05/14 16:37

  Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley

• TipRanks·05/14 15:16

  Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

• TipRanks·05/08 12:59

  Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

• Dow Jones·05/08 12:11

  Generate Biomedicines Price Target Raised to $25.00/Share From $16.00 by HC Wainwright & Co.

• Dow Jones·05/08 12:11

  Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·05/08 12:00

  HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

• TipRanks·05/08 10:32

  Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright

• Reuters·05/08 10:29

  GENERATE BIOMEDICINES, INC. <GENB.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $16